Peptide Knowledge Base · GH-axis
MK-677 (Ibutamoren): what it is, what the evidence says, and its real status
An orally-active growth-hormone secretagogue, not a peptide, studied for GH/IGF-1 and appetite.
Short version: an oral GH secretagogue people lump in with peptides, it isn't one. Education only here; it raises GH/IGF-1 and appetite, with real metabolic cautions.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Education only · Education only.
Not offered, education only. MK-677 is an oral GH secretagogue (an investigational drug, not a peptide). It raises GH/IGF-1 but can increase appetite, blood sugar, and water retention.
How does MK-677 (Ibutamoren) work?
A non-peptide ghrelin-receptor agonist taken orally that sustains elevated growth hormone and IGF-1 levels.
What it does — and what it does not do
What it does: Raises GH and IGF-1 and stimulates appetite; studied for body composition and sleep.
What it does not do: It is not a peptide, not FDA-approved, and not offered here.
How honest is the evidence?
Evidence grade C — human GH/IGF-1 data exists; long-term outcome and safety data limited. Read our grading methodology for what each grade means.
What we still don't know: Effects on long-term glucose metabolism and cardiac parameters need more data.
WADA status: Banned (S2).
How it is taken
Not offered; education only.
Who should not take it
Caution with diabetes/insulin resistance and heart failure (fluid retention); WADA S2 banned.
Sources
Ibutamoren (MK-677) GH/IGF-1 clinical literature
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.